WASHINGTON, April 10, 2013 – Gardasil, the vaccine for HPV (human papillomavirus), may not be as safe as backers claim.
Judicial Watch announced it has received documents from the Department of Health and Human Services (HHS) revealing that its National Vaccine Injury Compensation Program (VICP) has awarded $5,877,710 dollars to 49 victims in claims made against the highly controversial HPV (human papillomavirus) vaccines. To date 200 claims have been filed with VICP, with barely half adjudicated.
“This new information from the government shows that the serious safety concerns about the use of Gardasil have been well-founded. Public health officials should stop pushing Gardasil on children.” said Judicial Watch President Tom Fitton.
The CDC recommends the Gardasil vaccine, made by Merck Pharmaceuticals, for all females between 9 and 26 years to protect against HPV. Furthermore, the CDC says Gardasil is licensed, safe, and effective for males ages 9 through 26 years.
The facts appear to contradict the FDA’s safety statements. The adverse reaction reports detail 26 new deaths reported between September 1, 2010 and September 15, 2011 as well as incidents of seizures, paralysis, blindness, pancreatitis, speech problems, short term memory loss and Guillain-Barré Syndrome. The documents come from the FDA’s Vaccine Adverse Event Reporting System (VAERS) which is used by the FDA to monitor the safety of vaccines.
That’s 26 reported deaths of young, previously healthy, girls after Gardasil vaccination in just one year.
In response to the concern about death reports among those who received Gardasil, the Centers for Disease Control (CDC) insists “there was no unusual pattern or clustering to the deaths that would suggest that they were caused by the vaccine.”
While it is not clear exactly what is causing so many adverse reactions, Gardasil does contain genetically engineered virus-like protein particles as well as aluminum, which can affect immune function.
Further, according to the vaccine manufacturer product information insert, “Gardasil … not been evaluated for carcinogenicity or impairment of fertility.” (2007  p1986 )
In fact, Merck studied the Gardasil vaccine in fewer than 1,200 girls under 16 prior to it being released to the market under a fast-tracked road to licensure. To date, most of the serious side effects, including deaths, that occurred during the pre-licensure clinical trials and post marketing surveillance have been written off as a “coincidence” by Merck researchers and government health officials.
Neurologist Dr. Ian Sutton reported negative neurological side effects from Gardasil. He reported five cases of multiple sclerosis-like symptoms emerging shortly after women received the Gardasil vaccine, noting:
“We report five patients who presented with multifocal or atypical demyelinating syndromes within 21 days of immunization with the quadrivalent human papilloma virus (HPV) vaccine, Gardasil. Although the target population for vaccination, young females, has an inherently high risk for MS, the temporal association with demyelinating events in these cases may be explained by the potent immuno-stimulatory properties of HPV virus-like particles which comprise the vaccine.”
From its inception, the use of HPV (human papillomavirus) vaccines for sexually transmitted diseases has been hotly disputed. According to the Annals of Medicine: “At present there are no significant data showing that either Gardasil or Cervarix (GlaxoSmithKline) can prevent any type of cervical cancer since the testing period employed was too short to evaluate long-term benefits of HPV vaccination.”
There are more than 100 types of human papillomaviruses (HPVs). Of them, about 40 types of HPV are sexually transmitted and 15 of these types are most associated with cervical cancers and genital warts in women and men.
HPV vaccines have been illegally administered to millions without informed consent, as the risks rarely disclosed.
Not only are there questions about the safety of the vaccine, there are questions about the need for the vaccine. Over 90 percent of women infected with HPV clear the infection naturally within two years, at which point cervical cells go back to normal.
Meanwhile, Merck is benefitting tremendously from vaccine sales. The vaccine is expected to reach $1 billion in sales next year, and could reach more than $4 billion in sales in five years, according to Wall Street analysts.